Weekly Roundup: One month till Optimum’s Annual Healthcare Investor Conference
ViaNautis Bio welcomed SCI Ventures as new investor, expanding CNS portfolio into spinal cord injury
ViaNautis Bio, the biotech developing polyNaut® for precise, non‑viral delivery of genetic medicines, announced that SCI Ventures, a specialist venture fund backed by leading clinical centres and research foundations worldwide focused on advancing treatments and cures for paralysis, has joined the company as a new investor. The investment supports the application of ViaNautis’ polyNaut® platform to regenerative therapies for spinal cord injury, where targeted delivery remains a huge barrier.
Biocomposites to host industry symposium and present new STIMULAN® data at EBJIS-MSIS 2026
Biocomposites, an international medical devices company that engineers, manufactures and markets world-leading products for use in infection management in bone and soft tissue, announced its participation as a Platinum Sponsor of the 44th Annual Meeting of the European Bone & Joint Infection Society (EBJIS) – in cooperation with the Musculoskeletal Infection Society (MSIS), taking place in Porto, Portugal, from 17–19 September 2026.
Minoryx and Neuraxpharm complete enrolment in leriglitazone pivotal Phase 3 trial (CALYX) in adult patients with cerebral Adrenoleukodystrophy (cALD)
Minoryx Therapeutics and Neuraxpharm Group (Neuraxpharm), announced that the last patient has been enrolled in the Phase 3 clinical trial (CALYX) evaluating leriglitazone (NEZGLYAL®) in adult male patients with cerebral Adrenoleukodystrophy (cALD), an orphan neurodegenerative disease with no pharmacological therapeutic options.
CONNECTA Therapeutics announced financing to advance clinical development of Fragile X Syndrome programme
CONNECTA Therapeutics, a clinical-stage biotech company pioneering first-in-class neuroplasticity modulators to address unmet medical needs in central nervous system (CNS) disorders, announced that it has closed a €3.1 million financing led by new investor Clave Capital, through its Innvierte Science Tech Clave Innohealth, F.C.R. fund, and supported by existing investors Inveready, CDTI Innvierte and Prous Institute for Biomedical Research. Proceeds will support completion of ongoing Phase IIa trial of CTH120 in Fragile X syndrome, with topline data readout expected in mid-2027.
Teitur Trophics announced successful results from its Phase I clinical trial of first-in-class Parkinson’s disease peptide TT-P34
Teitur Trophics, a biotechnology company developing novel neuroprotective peptides for neurodegenerative diseases, announced successful results from the Phase I clinical trial of its lead asset TT-P34 in healthy volunteers and patients with early-stage Parkinson’s disease (PD).
Scenic Biotech appointed renowned neurology drug development leader Dr. Judith Walker as Chief Medical Officer
Scenic Biotech, a neurometabolic company whose function-first genomics engine has identified a first-in-class therapy to restore lysosomal function, a core driver of neurodegeneration in many diseases, announced the appointment of Dr. Judith Walker, MD, as Chief Medical Officer (CMO). Dr. Walker joins Scenic at a pivotal stage in its evolution as the Company advances SC6177 towards the initiation of clinical development in early 2027 and builds the capabilities required to become a clinical-stage biotechnology company.
Actithera strengthens leadership team and Board with appointments of Steven Kelly as CEO, Briggs Morrison as Chair, and John Crowley as Independent Director
Actithera, a radiopharmaceutical biotech company translating medicinal chemistry insights into next-generation radioligand therapies (RLTs), announced the appointment of Steven Kelly as Chief Executive Officer and a member of its Board of Directors, alongside the appointments of Briggs Morrison as Chair of the Board and John Crowley as an independent director, as the company advances into clinical development and enters its next phase of growth.
Resolution Therapeutics completed enrolment in its Phase I/II EMERALD clinical trial evaluating RTX001 in end-stage liver disease
Resolution Therapeutics, a clinical-stage biopharmaceutical company pioneering Regenerative Macrophage Therapy (RMT) in inflammatory and fibrotic diseases, announced that the final patient has been treated in EMERALD, the Company’s Phase I/II clinical trial evaluating its engineered RMT, RTX001, in patients with end-stage liver disease (ESLD) and a history of decompensated liver cirrhosis. Interim data are expected in the fourth quarter of 2026.
🌟 European Lifestars Awards
We’re incredibly proud to see so many of Optimum’s clients recognised as nominees in this year’s LSX European Lifestars Awards 2026!
From groundbreaking biotech and medtech companies to innovative investors and transformative deals, these nominations are a fantastic reflection of the strength, ambition and innovation across Europe’s life sciences sector.
A huge congratulations to all of our clients who have been nominated across this year’s categories. We’re proud to support you on your journey and thrilled to see your achievements recognised on the European stage.
Wishing all the nominees the very best of luck!
📺 Optimum TV: Countdown to Conference
With Optimum’s Annual Healthcare Investor Conference now one month away, watch our CEO, Mary Clark, talk with Leopoldo Zambeletti, a legend in the life science investment world, who during almost two decades as an investment banker led the European healthcare investment teams at both J.P. Morgan and Credit Suisse.
Leopoldo will be joining a panel at Optimum’s conference discussing how to unlock the full potential of Europe’s life science ecosystem.
In this curtain-raiser, Leopoldo gives some initial thoughts on where Europe has an edge and where the continent is lagging behind, as well as what’s been driving 2026’s M&A boom.
Watch the episode here:
👥Industry events
Optimum’s 18th Annual Healthcare Investor Conference
London | 8 October 2026
Our agenda is now live, featuring leading voices from the life sciences and investment communities. Attendance is strictly limited and by invitation only, so register your interest today.
BIO-Europe 2026 – Cologne, Germany | 9–11th Nov 2026
Connecting with the global biotech community – Our CEO, Mary Clark, and Associate Director Zoe Bolt will be attending BIO-Europe 2026, one of the leading international dealmaking events for the life sciences industry.
The team are looking forward to meeting with companies, investors and potential partners to discuss collaboration opportunities. Get in touch to schedule a get-together.
London Landmarks Run | 17 November 2026
Optimum Strategic Communications and Catalyst Advisors LP will be hosting a 5K #LondonLandmarksRun during the #Jefferies Global Healthcare Conference and London Life Sciences Week this November.
Start your day the right way with the London Landmarks Run. Connect with fellow #LifeSciences professionals while taking in some of London’s most iconic sights before the London Life Sciences/Jefferies conference day begins in November.
🕰️ ~7.00am GMT
🔗 Register for more information: Optimum & Catalyst Advisors 5K London Landmarks Run @ Jefferies HC 2026
Jefferies Global Healthcare Conference & London Life Sciences Week – London | 15–20th Nov 2026
📅 Heading to the Jefferies Global Healthcare Conference and London Life Sciences Week this November?
Register to join the mailing list and receive the official Jefferies Networking Event Guide, produced by Optimum Strategic Communications and Catalyst Advisors LP in partnership with Jefferies.
🔗 Register here: The Event Guide: Jefferies Global Healthcare Conference & London Life Sciences Week 2026 – Optimum Strategic Communications
📍 Planning an event during Jefferies Global Healthcare Conference or London Life Sciences Week 2026? Email the Optimum team at contact@optimumcomms.com to have your event included in the guide.
Sponsorship Opportunities – Anglonordic Europe Life Science Conference
Join us as a sponsor of the 23rd Anglonordic Europe Life Science Conference on 20 April 2027 and position your organisation at the heart of the European life sciences community.
Our sponsorship packages offer a valuable opportunity to raise your profile, showcase your expertise, and connect with investors, biotech leaders, pharma executives and other key decision-makers from across the sector. Whether your goal is to increase brand visibility, generate new business opportunities or demonstrate your commitment to innovation, we have a range of sponsorship options available.
📩 To discuss sponsorship opportunities, contact anglonordic@optimumcomms.com
🔗 Learn more: Sponsors – Anglo Nordic Life Science Conference 2027
That’s all folks! To stay in the know – subscribe to Optimum’s weekly wrap-up today!
